LINDIS Biotech Consolidates Onco-Immune, Trifunctional, Bispecific Antibody IP and Know-How from TRION Pharma
Horst Lindhofer, CEO of LINDIS Biotech and inventor of the trifunctional antibody technology succeeded in regaining the relevant IP and know-how from TRION Pharma out of the insolvency proceedings. Currently, LINDIS consolidates these patents and know-how with relevant LINDIS IP and hosts several advanced trifunctional antibody programs. The company plans to hire a limited number of highly experienced staff to continue clinical development once it has raised additional capital.
Dr Horst Lindhofer explained: “We seek to capitalise the company that now houses a pipeline of three new potential treatments against malignant tumours based on the trifunctional platform. One is in late pre-clinical and two are in Phase I/II clinical stage. The fund-raising comes at a great time given the compelling and positive clinical update of our Lymphomun programme.”
“When the industry converted to human/humanised antibodies, we chose to further develop our murine-based antibody platform due to its vaccination effect and the direct tumour-cell-killing potential that we discovered as early as 1997. Today we are unique because of this special characteristic. Our powerful effects on solid tumours were first verified in 2006,” explained Dr Lindhofer.
“We are grateful to our advisors, IMI Consulting GmbH (IMI) and Partners, for supporting us during the TRION Pharma insolvency process. IMI will now resume the discussions with potential investors for Round A,” Dr Lindhofer further added.
“The trifunctional antibody therapy is a platform that carries the hopes of cancer patients worldwide as it triggers the patient’s own immune system to recognise and destroy the cancer cells and, moreover, to induce a lasting immune memory against the individual mutations of the patient’s tumour cells. These antibodies can easily be adapted to fight many different types of cancers,” added Dr Lindhofer
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance